Pharmaceutical Company
Issues generally related to the Orphan Drug Tax Credit. Issues generally related to: bio-pharmaceutical drugs and drug development programs, including but not limited to Orphan Drug Act incentives; drug pricing proposals; access to rare disease and gene therapy drugs, newborn screening and gene panel screening; and FDA approvals of drugs designed to treat rare diseases. Issues generally related to: bio-pharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs.
TAX - Taxation/Internal Revenue Code HCR - Health Issues MMM - Medicare/Medicaid
34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 34 - Health & Human Services, Dept of (HHS) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CHAMBER HILL STRATEGIES
3325 N Kensington Street, Arlington, VA, 22207, US
MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN MELISSA BARTLETT (Counsel, U.S. House of Representatives, Committee on Energy and Commerce) ANNA KATHERINE WEINSTEIN
Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce Counsel, U.S. House of Representatives, Committee on Energy and Commerce